Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Mineralys Therapeutics Inc shares valued at $75,398 were sold by Rodman David Malcom on Nov 11 ’24. At $15.00 per share, Rodman David Malcom sold 5,026 shares. The insider’s holdings dropped to 140,991 shares worth approximately $1.85 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Rodman David Malcom purchased 5,026 shares, netting a total of over 75,398 in proceeds.
Before that, Rodman David Malcom had sold 25,482 shares from its account. In a trade valued at $383,066, the Chief Medical Officer traded Mineralys Therapeutics Inc shares for $15.03 each. Upon closing the transaction, the insider’s holdings decreased to 25,482 shares, worth approximately $1.78 million.
As published in their initiating research note from H.C. Wainwright on July 10, 2024, Mineralys Therapeutics Inc [MLYS] has been a Buy and the price target has been revised to $30. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early April. As of March 07, 2023, Wells Fargo has initiated its “an Overweight” rating for MLYS. Earlier on March 07, 2023, Stifel initiated its rating. Their recommendation was “a Buy” for MLYS stock.
Analyzing MLYS Stock Performance
During the last five days, there has been a surge of approximately 4.05%. Over the course of the year, Mineralys Therapeutics Inc shares have jumped approximately 52.44%. Shares of the company reached a 52-week high of $16.91 on 02/27/24 and a 52-week low of $7.95 on 01/18/24. A 50-day SMA is recorded $13.11, while a 200-day SMA reached $12.83. Nevertheless, trading volume fell to 95923.0 shares from 0.21 million shares the previous day.
Support And Resistance Levels for Mineralys Therapeutics Inc (MLYS)
According to the 24-hour chart, there is a support level at 12.72, which, if violated, would cause prices to drop to 12.32. In the upper region, resistance lies at 13.35. The next price resistance is at 13.58. RSI (Relative Strength Index) is 51.25 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.06, which suggests the price will decrease in the coming days. Percent R is at 51.60%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
